Genotypic Resistance at Viral Rebound among Patients Who Received Lopinavir/ritonavir- or Efavirenz-Based First Antiretroviral Therapy in South Africa

NNRTI drug resistance mutations (DRM) are increasingly reported in Africans failing their first antiretroviral regimen. The Phidisa II trial randomized treatment-naïve participants to LPV/r or EFV with d4T+3TC or ZDV+ddI. We report the prevalence of DRM in subjects who achieved HIV RNA < 400 copi...

Full description

Saved in:
Bibliographic Details
Main Authors: Dlamini, J. Nomthandazo, Hu, Zonghui, Ledwaba, Johanna, Morris, Lynn, Maldarelli, Frank M., Dewar, Robin L., Highbarger, Helene C., Somaroo, Harsha, Sangweni, Phumelele, Follmann, Dean A., Pau, Alice K.
Format: Artigo
Language:Inglês
Published: 2011
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3197956/
https://ncbi.nlm.nih.gov/pubmed/21694608
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0b013e3182278c29
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items